The first authorized generic version of Thiola® (tiopronin; Mission Pharmacal Company) has been made available by Teva Pharmaceuticals. 

Tiopronin is a reducing and complexing thiol indicated, in combination with high fluid intake, alkali, and diet modification, to prevent cystine stone formation in patients 9 years of age and older with severe homozygous cystinuria who are not responsive to these measures alone.

Due to Mission Pharmacal Company’s marketing exclusivity rights, Teva’s generic drug product is not labeled with additional pediatric use information.

Continue Reading

The generic product is available as 100mg tablets in 100-count bottles.

References

  1. Teva announces the U.S. launch of the first generic version of Thiola® (tiopronin) tablets. [press release]. Tel Aviv, Israel and Parsippany, NJ: Teva Pharmaceuticals; May 17, 2021. 
  2. Tiopronin [package insert]. Parsippany, NJ: Teva Pharmaceuticals USA, Inc.; 2021.

This article originally appeared on MPR

Topics:

Miscellaneous Urogenital Disorders Urologic Disorders